ArticleInfection and immunity2021
Pharyngeal Microbial Signatures Are Predictive of the Risk of Fungal Pneumonia in Hematologic Patients.
Article in Infection and immunity, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 14 citations in OpenAlex.
- Protective Effect of Indole-3-Aldehyde in Murine COVID-19-Associated Pulmonary Aspergillosis.Journal of fungi (Basel, Switzerland) · 2024Article
- Bacteria and fungi of the lung: allies or enemies?Frontiers in pharmacology · 2024Review
- Bridging of host-microbiota tryptophan partitioning by the serotonin pathway in fungal pneumonia.Nature communications · 2023Article
- Turning Microbial AhR Agonists into Therapeutic Agents via Drug Delivery Systems.Pharmaceutics · 2023Review
- From the nose to the lungs: the intricate journey of airborne pathogens amid commensal bacteria.American journal of physiology. Cell physiology · 2022Review
- A High-Risk Profile for Invasive Fungal Infections Is Associated with Altered Nasal Microbiota and Niche Determinants.Infection and immunity · 2022Observational
- Pharmaceutically Active Microbial AhR Agonists as Innovative Biodrugs in Inflammation.Pharmaceuticals (Basel, Switzerland) · 2022Review
- Optimizing therapeutic outcomes of immune checkpoint blockade by a microbial tryptophan metabolite.Journal for immunotherapy of cancer · 2022Article
- Lung and gut microbiomes in pulmonary aspergillosis: Exploring adjunctive therapies to combat the disease.Frontiers in immunology · 2022Review
- A Shifted Composition of the Lung Microbiota Conditions the Antifungal Response of Immunodeficient Mice.International journal of molecular sciences · 2021Article
- Risky Business: Oropharyngeal Bacteria Linked to Risk for Invasive Fungal Infection.Infection and immunity · 2021Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
30 authors at 10 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The ability to predict invasive fungal infections (IFI) in patients with hematological malignancies is fundamental for successful therapy. Although gut dysbiosis is known to occur in hematological patients, whether airway dysbiosis also contributes to the risk of IFI has not been investigated. Nasal and oropharyngeal swabs were collected for functional microbiota characterization in 173 patients with hematological malignancies recruited in a multicenter, prospective, observational study and stratified according to the risk of developing IFI. A lower microbial richness and evenness were found in the pharyngeal microbiota of high-risk patients that were associated with a distinct taxonomic and metabolic profile. A murine model of IFI provided biologic plausibility for the finding that loss of protective anaerobes, such as
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.